11/7/2012

Data from a midstage trial showed diabetes patients who added Poxel's imeglimin compound to sitagliptin treatment attained a 0.73% reduction in A1C at 12 weeks compared with the sitagliptin-placebo group, a study showed. The findings will appear in Diabetes Care.

Full Story:
Medical News Today

Related Summaries